Wednesday, October 14, 2026

Corporate Performance

3 articles

Retail Earnings Beats Meet Conservative Guidance as Operating Costs Outpace Revenue Growth

Retail Earnings Beats Meet Conservative Guidance as Operating Costs Outpace Revenue Growth

Major retailers are delivering Q4 earnings beats while issuing cautious forward guidance, driven by margin compression from rising operational expenses. 1-800-FLOWERS.COM's gross margin fell from 43.3% to 42.1% as operating expenses climbed $7.9M year-over-year, while February wholesale inflation rose 0.7% despite stable interest rates.

LM Salvado•
SanDisk stock surges 315% as AI infrastructure demand drives storage hardware rally

SanDisk stock surges 315% as AI infrastructure demand drives storage hardware rally

SanDisk shares jumped 315.3% while Western Digital gained 166.1% amid accelerating demand for high-capacity storage tied to AI infrastructure buildouts. Micron Technology secured contracts for its entire 2026 HBM supply and announced $20 billion in capital investments, signaling sustained momentum in the semiconductor storage sector.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com